NEW YORK, March 19, 2018 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Schmidt, Ph.D. will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. Dr. Schmidt will focus on the coverage of Biotech companies, working closely with our growing therapeutics team.
Dr. Schmidt will join Guggenheim from LEERINK Partners, where he has been an equity research analyst since 2009 and was named runner-up in the 2017 Institutional Investor All-America Research Survey in the Biotech/Mid- & Small-Cap category. Previous to joining LEERINK in 2009, he was a healthcare analyst and consultant for Susquehanna International Group’s private equity team. Dr. Schmidt was a research fellow at Harvard University previous to his work at Susquehanna.
“We are excited to have Michael join our growing healthcare equity research team,” said Stefano Natella, Director of Equity Research. “He represents an important next step in our plan to invest substantially in our research capabilities, particularly in the healthcare sector. We look forward to his continued success at Guggenheim.”
Michael Schmidt received his Ph.D. and M.Sc. from the University of Stuttgart in biochemistry and molecular genetics, respectively.
About Guggenheim Securities
Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, Los Angeles, San Francisco, and Houston. For more information, please contact us at [email protected] or 212.518.9200.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $305 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1Assets under management are as of 12.31.2017 and include consulting services for clients whose assets are valued at approximately $66bn.
Media Contact
Ellen Cunningham
Guggenheim Partners
212.518.9578
[email protected]


Apple Restores Telegram to App Store After Content Policy Violation
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
Jetstar to Charge for Overhead Cabin Bags From February
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
DeepSeek to Raise AI API Prices as Demand for New Models Surges
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 



